| Today’s Big NewsFeb 23, 2024 |
| By Kevin Dunleavy While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis. |
|
|
|
By Nick Paul Taylor GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the candidates to other companies while continuing to work with GSK on different respiratory pathogens. |
By Andrea Park As CEO Jim Hollingshead noted during the investor presentation, that increase represents Insulet’s “eighth consecutive year of 20-plus percent revenue growth” when calculated on a constant currency basis. |
By Kevin Dunleavy Along with host of other positive recommendations, European drug regulators rendered a positive opinion on Travere's Filspari for full approval in Berger’s disease. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By James Waldron Galapagos used its earnings report to disclose that work has been halted on a CD19 CAR-T candidate for refractory systemic lupus erythematosus. |
By Andrea Park The FDA issued a safety communication this week warning Americans that if they see a smartwatch or smart ring claiming to offer noninvasive blood sugar monitoring, the agency had nothing to do with it, thank you very much. |
By Angus Liu Even Alexander Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian. |
By Max Bayer Frontier Medicines has just closed a $80 million fundraising, but, according to CEO Chris Varma, Ph.D., corralling the capital was, in his own words, harder than the bleakest days of the Great Recession. |
By Conor Hale Making a simple and accurate blood test available to primary care providers would upend traditional diagnostic methods, where invasive spinal tap procedures or brain scans typically only come after a patient has begun demonstrating cognitive decline. |
By Max Bayer,Gabrielle Masson AbbVie has formally announced that President and COO Robert Michael will succeed Rick Gonzalez as CEO. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
|
Wednesday, March 13, 2024 | 11:00am ET/ 8:00am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
